Nuvalent shareholders should tender shares into the offer at $124.00/share. The deal carries a 40% premium and has strong insider support (28% already committed). Key risks are regulatory — FDA decisions on zidesamtinib (Sept 18) and neladalkib (Nov 27) — and HSR clearance. The stock should trade near the offer price minus a small spread for timing and regulatory risk. Monitor for any competing bids given the termination fee structure.
Price Chart
Executive Summary
GSK plc has agreed to acquire Nuvalent for $124.00 per share in cash, representing a total equity value of $10.6 billion. The transaction includes two late-stage ROS1 and ALK inhibitors (zidesamtinib and neladalkib) under FDA review with 2026 target action dates, plus a phase I HER2 inhibitor. Stockholders representing ~28% of Class A shares have signed tender and support agreements to tender their shares. The deal is expected to close in Q3 2026, subject to regulatory approval and a majority-of-shares tender condition.
Key Financial Metrics
Key Facts
- GSK to acquire Nuvalent for $124.00 per share in cash, aggregate equity value of $10.6 billion
- Purchase price represents a 40% premium to last closing price and a 26% premium to 30-day VWAP
- Two late-stage assets (zidesamtinib for ROS1+ NSCLC, neladalkib for ALK+ NSCLC) under FDA review with PDUFA dates of Sept 18, 2026 and Nov 27, 2026
- Third asset NVL-330 (HER2 inhibitor) in phase I for HER2-altered NSCLC
- Supporting stockholders (Deerfield affiliates, directors, officers) owning ~28% of Class A shares have agreed to tender
- Termination fee of $350,475,000 payable by Nuvalent under certain circumstances
- Transaction expected to close in Q3 2026; GSK expects low single-digit percentage dilution to core EPS in FY 2026-2028, accretion to core EPS in 2029
- GSK to fund primarily from new and existing debt plus cash; no financing condition
Financial Impact
$10.6 billion aggregate equity value; $124.00 per share cash consideration; net of cash acquired GSK's investment estimated at $9.4 billion
Risk Factors
- FDA non-approval or delayed approval of zidesamtinib or neladalkib could delay or jeopardize the deal
- HSR antitrust review could extend timeline or impose conditions
- Shareholder litigation could create delays or additional costs
- GSK's ability to fund the transaction is not subject to a financing condition, but debt markets could shift
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-262950 |
| Document: d137459dex101.htm | 0001193125-26-262950 |
| Document: d137459dex991.htm | 0001193125-26-262950 |
| Document: d137459d8k.htm | 0001193125-26-262950 |
| Document: 0001193125-26-262950-index-headers.html | 0001193125-26-262950 |
| Document: 0001193125-26-262950.txt | 0001193125-26-262950 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 15, 2026 11w ago | 25-NSE | $123.96 $123.96 | · 0.00% | ▲ +0.98% | — |
Jul 15, 2026 11w ago | 8-K | $123.96 $123.96 | · 0.00% | ▲ +0.98% | — |
Jul 8, 2026 12w ago | Insider Cluster | $123.80 $123.96 | ▲ +0.13% | ▼ −0.73% | — |
Jul 6, 2026 12w ago | Insider Cluster | $123.72 $123.90 | ▲ +0.15% | ▼ −0.34% | — |
Jun 11, 2026 16w ago | Insider Cluster | $123.25 $123.43 | ▲ +0.15% | ▼ −0.53% | — |
Jun 10, 2026 16w ago | Insider Cluster | $123.45 $123.36 | ▼ −0.07% | ▼ −0.51% | — |
Jun 9, 2026 16w ago | 8-K | $123.25 $123.35 | ▲ +0.08% | ▼ −2.33% | — |
May 7, 2026 21w ago | 8-K | $102.40 $105.22 | ▲ +2.75% | ▲ +1.25% | — |
Apr 29, 2026 22w ago | Insider Cluster | $99.10 $101.47 | ▲ +2.39% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access